My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

ADMA Biologics Inc - Common Stock (NQ:ADMA)

16.10 -0.22 (-1.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

3 Millionaire-Making Stock Picks With Astounding Growth Potential ↗

July 13, 2024

Owning millionaire-making stocks can be a life changer. Look no further than these three companies which are full of potential.

Via InvestorPlace

How Is The Market Feeling About ADMA Biologics? ↗

July 11, 2024

Via Benzinga

Bull Run Alert: 3 Stocks Set to Soar in the Coming Months ↗

July 11, 2024

Get ready for the next bull run with these stocks. All three are showing impressive growth and massive returns.

Via InvestorPlace

Expert Ratings For ADMA Biologics ↗

July 09, 2024

Via Benzinga

UroGen Pharma Stock Earns 91 RS Rating ↗

June 27, 2024

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

Via Investor's Business Daily

Arcellx Stock Earns Relative Strength Rating Upgrade ↗

June 21, 2024

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

Via Investor's Business Daily

Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights ↗

June 20, 2024

Via Benzinga

ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results ↗

May 10, 2024

Via Benzinga

A Closer Look at 6 Analyst Recommendations For ADMA Biologics ↗

March 26, 2024

Via Benzinga

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗

June 20, 2024

Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗

June 14, 2024

Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.

Via Investor's Business Daily

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗

June 12, 2024

On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.

Via Investor's Business Daily

Krystal Biotech Stock Sees RS Rating Jump To 91 ↗

June 11, 2024

On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.

Via Investor's Business Daily

Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday ↗

May 10, 2024

Via Benzinga

Forecasting The Future: 4 Analyst Projections For ADMA Biologics ↗

February 29, 2024

Via Benzinga

Recap: ADMA Biologics Q4 Earnings ↗

February 28, 2024

Via Benzinga

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 10, 2024

Via Benzinga

ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Earnings Preview For ADMA Biologics ↗

February 27, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For ADMA Biologics ↗

January 22, 2024

Via Benzinga

Earnings Preview: ADMA Biologics ↗

November 07, 2023

Via Benzinga

Preview: ADMA Biologics's Earnings ↗

August 08, 2023

Via Benzinga

Recap: ADMA Biologics Q1 Earnings ↗

May 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 09, 2024

Via Benzinga

Chart Of The Day: ADMA Biologics - Hitting New Highs ↗

May 06, 2024

100% technical buy signals 8 new highs and up 7.24% in the last month 110.10+ Weighted Alpha

Via Talk Markets

Why Adma Biologics Stock Crushed the Market on Friday ↗

November 17, 2023

The network of FDA-approved collection facilities continues to grow.

Via The Motley Fool

Why Adma Biologics Was Trouncing the Market Today ↗

November 09, 2023

The company beat analyst estimates for both revenue and profitability, and raised revenue guidance.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 08, 2023

Via Benzinga

Why Shares of ADMA Biologics Are Climbing Thursday ↗

August 10, 2023

The company, which focuses on infectious diseases, reported its second-quarter earnings on Wednesday after the markets closed.

Via The Motley Fool

AT&T, Carvana, Northern Trust, And Other Big Stocks Moving Higher On Wednesday ↗

July 19, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 250 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.